Medtronic plc.NYSE: MDT

Medtronic announces new prospective, global clinical evidence from the Spectrum Program for VenaSealTM closure system in advanced chronic venous disease

· Issued by Medtronic plc.

Summary by 6ix AI

Medtronic, a healthcare technology company, presented new prospective findings (from patients followed forward over time) from its global VenaSeal Spectrum Program for the VenaSeal closure system in chronic venous disease, a long-term vein condition. The findings were presented at the 2026 Venous Endovascular INterventional Strategies meeting.

Key details

  • Medtronic says the findings add to the evidence supporting the VenaSeal closure system across chronic venous disease.
  • Medtronic says recently expanded US payer coverage for the system now reaches 96% of commercially and Medicare insured lives.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/medtronic-announces-new-prospective-global-clinical-evidence-from-the-spectrum-program-for-venasealtm-closure-system-in-advanced-chronic-venous-disease

Watch Medtronic's latest callMedtronic PLC. (NYSE:MDT) Q1 2027 Earnings Call · Replay · Sep 1Read the transcript of Medtronic PLC. (NYSE:MDT) Q1 2027 Earnings Call
News comes on heels of recent expanded U.S. payer coverage, reaching 96% of commercially and Medicare insured lives, expanding greater access to care Medtronic, a global leader in healthcare technology, announced new prospective findings from the VenaSeal™ Spectrum Program, further strengthening the evidence supporting the VenaSeal™ closure system across chronic venous disease. The findings were presented at the 2026 Venous Endovascular INterventional Strategies 2026 [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Medtronic plc. on 6ix

Earlier from Medtronic

Later from Medtronic

All Medtronic news releases